NEUROSCIENCE, NEUROPHARMACOLOGY AND EXERCISE SCIENCE
Dr Jacob Thorstensen,
Neuroscientist & Assistant Professor,
Faculty of Health Sciences & Medicine
Bond University, Queensland, Australia &
Honorary Research Fellow
The School of Biomedical Sciences,
The University of Queensland
Queensland, Australia
RESEARCHER PROFILE
Filmed in the Gold Coast, Australia | November 2025
Dr Jacob Thorstensen is an early-career Assistant Professor in Neuroscience and Physiology in the Faculty of Health Sciences & Medicine at Bond University. He is also an honorary research fellow in The School of Biomedical Sciences at The University of Queensland.
Dr Thorstensen graduated first-class honours in exercise science, completed a PhD in neurophysiology at Griffith University, and completed a post-doctoral research fellowship in neurology at The University of Queensland.
His research uses non-invasive neurostimulation techniques to study how the brain and spinal cord control muscles in human subjects.
His findings have been published in several discipline-leading scientific journals including The Journal of Physiology, Journal of Neurophysiology and Neuropharmacology and disseminated at large, international scientific meetings.
His work has unveiled several new neuroscientific mechanisms which have future applications for movement disorders. Recent recognitions include being on the Forbes 30 Under 30 list for the Healthcare & Science Category (2024) and being selected as a Career Achievement Award finalist in the 7NEWS QLD Young Achiever Awards (2025).
Dr Thorstensen sits on the editorial boards for The Journal of Physiology and Journal of Applied Physiology.
He is a part of the executive committee for the Australasian Brain Stimulation Society, and the early career researcher and education committees for the International Society of Electrophysiology and Kinesiology.
He is also part of a team that has recently been funded through a Multiple Sclerosis Australia Incubator Grant for a neurostimulation project.
Source: Supplied
https://orcid.org/0000-0002-6821-1547
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Biomarkers for early sepsis detection
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
-
Biological interactions of extracellular vesicles
Raluca Ghebosu graduated from the University of Queensland with a Bachelor of Arts/Bachelor of Science with majors in Japanese and Biomedical Science (2018-2021). She then completed her Bachelor of Science (Honours) with the School of Biomedical Sciences at the University of Queensland in 2022, before pursuing a PhD with A/Prof. Joy Wolfram at the Australian Institute for Bioengineering and Nanotechnology.
